A new treatment for overdose caused by powerful opioids
Official title: NX90: A Treatment for Overdose Caused by High Potency Opioids
Funded at Serodopa Therapeutics INC · NIH-11008545 · Data updated 2026-11-12
This study is testing a new treatment that could help people who have overdosed on strong opioids like fentanyl, aiming to work faster and with fewer side effects than current options, so that those in crisis can get better help more quickly.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Serodopa Therapeutics INC NIH-funded |
| Lab location | 1 site (Gainesville, United States) |
| Project start | September 30, 2024 |
| Project end | August 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $1,539,426 |
| NIH project number | 1R44DA061722-01 |
| Project ID | NIH-11008545 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals at risk of opioid overdose, particularly those using high-potency opioids.
✕Less likely to help
Patients who do not use opioids or are not at risk of overdose may not benefit from this research.
What this research studies
This research focuses on developing a novel treatment to reverse overdoses from high-potency opioids like fentanyl. Current treatments, such as naloxone, often struggle to effectively counteract the effects of these potent drugs due to their rapid action and unique pharmacology. The new treatment aims to provide a faster and more effective response to opioid-induced respiratory depression, potentially using a modified version of naloxone that can work at lower doses and with fewer side effects. This could significantly improve outcomes for individuals experiencing an overdose.
Why it matters
Potential benefit: If successful, this research could lead to a more effective and safer treatment for opioid overdoses, potentially saving countless lives.
How similar studies have gone: While naloxone has been the standard treatment for opioid overdose, this approach is novel and aims to address the limitations of existing treatments, making it a potentially groundbreaking advancement.
Where this research is happening
-
Serodopa Therapeutics INC
Gainesville, United States Active
Researchers
- Principal investigator: Voronkov, Michael V. — Serodopa Therapeutics INC
- Study coordinator: Voronkov, Michael V.
Related research
Other NIH-funded projects on the same topics.
-
NX90: a faster overdose treatment for fentanyl and other powerful opioids
NX90 is a new naloxone-derived antidote designed to quickly restore breathing for people who overdose on fentanyl and other high-potency opioids.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.